These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31706732)

  • 1. Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study.
    da Silva PM; Aguiar C; Morais J;
    Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):559-569. PubMed ID: 31706732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: the ATTICA epidemiological cohort study (2002-2012).
    Georgoulis M; Chrysohoou C; Georgousopoulou E; Damigou E; Skoumas I; Pitsavos C; Panagiotakos D
    Lipids Health Dis; 2022 Dec; 21(1):141. PubMed ID: 36529737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry.
    Arnold SV; Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Alam S; Mues KE; Bhatt DL; Kosiborod M;
    J Am Heart Assoc; 2021 Aug; 10(16):e020893. PubMed ID: 34369165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.
    Hammoudeh AJ; Echtay A; Ghanem GY; Haddad J;
    Curr Med Res Opin; 2014 Oct; 30(10):1957-65. PubMed ID: 24889279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study.
    Jameson K; Amber V; D'Oca K; Mills D; Giles A; Ambegaonkar B
    Int J Clin Pract; 2013 Dec; 67(12):1228-37. PubMed ID: 23944233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study.
    Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Chretin S; Yin D; Alemao E; de Pouvourville G
    Atherosclerosis; 2006 Mar; 185(1):58-64. PubMed ID: 16038912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characterization of lipid profile in primary health care users in Portugal].
    Cortez-Dias N; Robalo Martins S; Belo A; Fiúza M;
    Rev Port Cardiol; 2013 Dec; 32(12):987-96. PubMed ID: 24280078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers.
    Mazzolini TA; Irons BK; Schell EC; Seifert CF
    J Manag Care Pharm; 2005; 11(9):763-71. PubMed ID: 16300420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
    Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
    Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
    Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipid control in patients with coronary artery disease in a healthcare area in Cáceres (Spain): LIPICERES study].
    Gómez-Barrado JJ; Ortiz C; Gómez-Turégano M; Gómez-Turégano P; Garcipérez-de-Vargas FJ; Sánchez-Calderón P
    Clin Investig Arterioscler; 2017; 29(1):13-19. PubMed ID: 28062171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy.
    Figliuzzi I; Presta V; Citoni B; Miceli F; Simonelli F; Battistoni A; Coluccia R; Ferrucci A; Volpe M; Tocci G
    Clin Cardiol; 2018 Jun; 41(6):788-796. PubMed ID: 29604091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.